Novartis has decided not to proceed with the second part of its midstage trial of Fabhalta (iptacopan) for lupus nephritis, after completing the first part.
The company said the decision was based on “strategic considerations,” not interim efficacy or safety findings. It has not publicly detailed those strategic considerations.
The two-part study enrolled about 81 people with active lupus nephritis and tested Fabhalta alongside standard care. Investigators have been notified and are working with participants on next steps.
Novartis says its Fabhalta studies in other indications will continue as planned. The available reports do not provide results from the completed first part of this trial.
Sources:
Novartis pauses midstage Fabhalta trial in lupus nephritis—but efficacy, safety not at play
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
Novartis Discontinues Mid-Stage Fabhalta Trial in Lupus ...
Novartis ends mid-stage trial for Fabhalta in lupus nephritis
Novartis halts mid-stage trial for kidney drug, Fabhalta, in ...
Novartis stopt mid-stage trial voor Fabhalta bij lupus nefritis Door Investing.com
Novartis halts mid-stage trial for kidney drug, Fabhalta (NVS)
Novartis abandons Fabhalta trial in lupus nephritis
Novartis ends mid-stage Fabhalta trial targeting serious ...
Novartis stoppt Fabhalta-Studie bei Lupusnephritis
Novartis ends mid-stage Fabhalta trial targeting serious ...
Novartis ends mid-stage trial for Fabhalta in lupus nephritis By Investing.com